Surgery Versus Internal Radiation in Treating Patients With Stage II Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed adenocarcinoma of the prostate within the past 120 days
• * T1c-T2a, N0, M0
• No bilateral disease
• Prostate-specific antigen (PSA) no greater than 10 ng/mL
• * In patients with prior neoadjuvant hormonal therapy (NHT), PSA must be less than 10 ng/mL prior to therapy
• Gleason score no greater than 6
• Prostate gland less than 60 cc on transrectal ultrasound or with minimal pubic arch interference OR
• Prostate gland 60 cc or greater prior to NHT allowed if prostate size has been reduced to less than 60 cc by NHT
• PATIENT CHARACTERISTICS:
• Age:
• 75 and under
• Performance status:
• ECOG 0-2 OR
• Zubrod 0-2
• Renal:
• Creatinine no greater than 3 mg/dL
• Cardiovascular:
• No significant cardiovascular disease
• No New York Heart Association class III or IV heart disease
• Other:
• No other malignancy within the past 5 years except effectively treated basal cell or squamous cell skin cancer or other malignancy at low risk for recurrence
• No other condition that would preclude study
• PRIOR CONCURRENT THERAPY:
• Endocrine therapy:
• See Disease Characteristics
• At least 90 days since prior NHT
• * Duration of therapy no greater than 120 days
• No concurrent NHT
• Radiotherapy:
• No prior radiotherapy to pelvis
• Surgery:
• No prior surgery for prostate cancer or benign disease, including:
• * Transurethral resection of the prostate
• * Transurethral resection of the bladder neck
• * Cryotherapy
• * Laser ablation
• * Microwave therapy